Data from the Phase I trial showed that the cancer vaccine offered an 86 percent reduction in the risk of relapse or death in pancreatic and colorectal cancers.
List view / Grid view
University of Texas MD Anderson Cancer Center
Clinical development and manufacture of microbiome-based therapeutics is set to be accelerated through Kanvas Biosciences’ new acquisition of key assets from Federation Bio.
A Phase II clinical trial using combination therapy to treat leukaemia has shown positive results, with a Phase III clinical trial initiated...